What the Supreme Court's Pay-for-Delay Decision Means for Investors

The Supreme Court has delivered a number of important verdicts, with a few more on the way. One such decision important to the health-care industry is on so-called pay-for-delay tactics.

When a drug's patent protection is in dispute, and generic-drug companies routinely challenge the patents of high-profile drugs, a Big Pharma can essentially settle the case by paying a generic-drug company off to not produce a low-cost version of its product, at least for a little while. 

In this video, health-care analyst David Williamson takes a look at how this decision alters pay-for-delay, how it affects Big Pharma and generic-drug makers, and what it all means for investors.

In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.

Follow David on Twitter: @MotleyDavid.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2504413, ~/Articles/ArticleHandler.aspx, 4/20/2014 10:35:36 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement